Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page % ^9 L, \! k/ o8 ]- I
8 l9 W, U2 b+ r5 d2 @
* ?5 i% X% {% G0 \: L
Sub-category:
" B/ Q0 v- K: G8 R9 C# {Molecular Targets
# K0 g/ c+ \6 i; g! o i" y# I, }6 w- f
' r2 \$ W% C( o \# KCategory:+ u ~$ \/ ^- W) ^% R1 X
Tumor Biology |9 t2 L# U" [/ u; I, H
0 i6 A5 \2 _* r( R" F" V
4 y7 h$ D9 l- W/ r/ `) C/ v( k: iMeeting:6 F, m* e- Z5 H& s
2011 ASCO Annual Meeting m5 S+ z+ Y. g, q
/ l# \, `! [- e' M2 q2 Q) @0 j6 U! k
+ A; m' b3 _9 v9 z* cSession Type and Session Title: r: _" b( L, f0 h5 _4 o
Poster Discussion Session, Tumor Biology
( W9 D0 e: X( S, a5 w/ R
, M, t! p8 c" W W# z/ i
1 ~3 a# U% S3 [) z- w4 M( D7 Y# H* RAbstract No:$ x* A( M& }) M9 x
10517 0 s2 M0 ^* J. x4 \* @+ B
; t- c( T# { i, @ K. u9 x5 Q- Y
1 ~( Y6 J* ^9 XCitation:
) a F$ `( a+ K9 M6 m" A6 k: QJ Clin Oncol 29: 2011 (suppl; abstr 10517)
0 E; C4 W- h {1 L% C0 u5 Q/ W- L) g+ }! t9 \, g5 w7 S' K: X
2 H# @' f/ n3 `$ g8 Z7 X7 x% NAuthor(s):
# z- K9 A9 B, h( Z+ p/ c: yJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China ) l# t; a: p( Q/ C5 ^2 s# u
- A$ A. g( ~8 l* N8 i R6 c8 \, _
" G* k+ L! z! ~" t. b; x7 `0 K+ U2 o9 h% L
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.1 f! |# W8 u$ ?- h% S9 w
0 N/ z Z: N, I+ eAbstract Disclosures
4 \0 M0 K t3 Q" ]: z6 N
/ T' Y& \0 h7 ` MAbstract:
- `$ X/ l" c. O& r5 l9 F( {( {+ c
! E9 d$ T5 `) C* |' X \' c; ?8 k
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
; X4 }; i& [, n! D' t- Q. Z% A, L6 A- n
) v0 k y1 Z; n0 k+ T+ m; [8 S
|